Sonia Anand, MD, PhD, FRCPC

Dr. Sonia Anand is a Professor of Medicine and Epidemiology at McMaster University, the Director of McMaster Population Genomics Program and a vascular medicine specialist. She recently received the Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. She also holds the Heart and Stroke Foundation of Ontario/Michael G. DeGroote Chair in Population Health Research. Her present research focuses upon the environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease. Past education includes an undergraduate degree in Life Sciences from Queen?s University in 1989, a Doctor of Medicine from McMaster in 1992, Internal Medicine Training at McMaster and a Fellowship of the Royal College of Physicians and Surgeons of Canada in 1996. She further received her Master?s in Clinical Epidemiology at McMaster in 1996 and Ph.D. in Health Research Methodology at McMaster in 2002. She completed a Heart and Stroke Foundation of Canada Research Fellowship in 1998, and in 2001 completed a Vascular Medicine Fellowship at Harvard University?s Brigham and Women's Hospital. In 1996, Dr. Anand received a Canadian Institutes of Health Research Clinician Scientist Award Phase 1 followed by the Phase 2 Award which she held from 2003-2008. She held the Eli Lily/May Cohen Chair in Women?s Health Research at McMaster from 2006-2013. Dr. Anand?s work is widely published amongst academic and peer-evaluated journals and she teaches clinical epidemiology courses in methodology and cardiovascular disease at McMaster University.

Jeffrey S. Berger, MD, MS, FAHA, FACC

Jeffrey S. Berger, M.D., M.S. is Director of Cardiovascular Thrombosis and Assistant Professor of Medicine and Surgery in the Divisions of Cardiology, Hematology, and Vascular Surgery at the New York University School of Medicine. Dr Berger has a particular interest in atherothrombosis including the study of platelet activity, antithrombotic therapy, and peripheral artery disease. Platelet activity phenotyping and genotyping are used to explore the mechanism of atherothrombosis and consequences of different antiplatelet therapies.

Dr. Berger is a recipient of several grants from the National Institutes of Health, American Heart Association, and Doris Duke Charitable Foundation for his studies on platelet activity in different phenotypes of vascular disease. Dr Berger has amassed several awards for his research, including Young Investigator Awards from the American Heart Association, Annual Platelet Colloquium, Society of Vascular Medicine, University of Pennsylvania, and NYU School of Medicine. Prior to joining NYU, Dr Berger completed a fellowship in Vascular Medicine and Thrombosis and Hemostasis at the University of Pennsylvania, Cardiology at Duke University and a Cardiovascular Clinical Research Fellowship at the Duke Clinical Research Institute. Dr. Berger was Resident and Chief Resident in Internal Medicine at Beth Israel Medical Center, completed a Master?s Degree in Clinical Research at the Albert Einstein College of Medicine, and graduated from Sackler School of Medicine.

Alan Daugherty, PhD, DSc, FAHA

Alan Daugherty was born in Liverpool, England. He completed his undergraduate studies in Pharmacology at Sunderland Polytechnic, and received both a Ph.D. and a D.Sc. from the University of Bath. He moved to Washington University in St. Louis for fellowship training on lipoprotein metabolism and atherosclerosis. Subsequently, he was appointed to the faculty in the Division of Cardiovascular Medicine. He continued his studies on mechanisms of lipoprotein modification and immune function on the development of atherosclerosis. These studies also including imaging studies using chemical adducts for noninvasively detecting lipoprotein catabolism by a number of modalities. In 1997, he moved to the University of Kentucky in Lexington where he is now the Senior Associate Dean for Research in the College of Medicine and Director of the Saha Cardiovascular Research Center. Through the generosity of Linda and Jack Gill, he was also awarded the Gill Foundation Chair of Preventive Cardiology. Within the strong collaborative environment for cardiovascular research at the University of Kentucky, he has participated in studies on the role of angiotensin peptides in the development of atherosclerosis and aortic aneurysms. He is highly committed to the research, advocacy, and educational missions of the American Heart Association and currently serves as Editor-in-Chief of Arteriosclerosis, Thrombosis, and Vascular Biology (AVTB).

Jennifer Doudna, PhD

Jennifer Doudna is the Li Ka Ching Chancellor?s Chair in Biomedical and Health Sciences and she is Professor of Molecular and Cell Biology and Professor of Chemistry at UC Berkeley and an Investigator of the Howard Hughes Medical Institute. She received her undergraduate degree in Biochemistry from Pomona College in 1985 and her Ph.D. in Biological Chemistry from Harvard University in 1989. After completing postdoctoral work at the University of Colorado at Boulder, she joined the Yale University faculty in 1994, where she was promoted through the ranks to Henry Ford II Professor of Molecular Biophysics and Biochemistry in 1999. In 2002 she joined the faculty at UC Berkeley. Prof. Doudna is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Inventors. She is a recipient of awards including the NSF Waterman Award, the FNIH Lurie Prize, the Paul Janssen Award for Biomedical Research and the Breakthrough Prize in Life Sciences.

Xiaoping Du, MD, PhD

Xiaoping Du received medical degree from Suzhou Medical College (now Soochow University College of Medicine), China, and PhD degree from the University of Sydney, Australia. He is currently a tenured Professor and Director of Vascular Biology Program in the Department of Pharmacology, University of Illinois at Chicago. His research has been in areas of platelets and thrombosis, particularly signaling mechanisms of platelet adhesion receptors integrin ?IIb?3 and GPIb-IX. His recent discoveries include the direct binding of G?13 protein to integrins as a mechanism of integrin outside-in signaling, as well as a new anti-thrombotic approach based on this interaction. His works are published in quality scientific journals such as Nature, Science, Cell, ATVB and Blood. Xiaoping Du served as a member of Hemostasis and Thrombosis study section and other NIH study sections, Thrombosis review group for AHA, and the Scientific Committee on Platelets of the American Society of Hematology. He is currently actively involved in ATVB council as a member of editorial board of ATVB journal, and as a member of ATVB program committee for AHA Scientific Sessions. He has received Special Recognition Award in Thrombosis from ATVB council, University Scholar Award and Distinguished Researcher Award from the University of Illinois.

Jane E. Freedman, MD

Dr. Jane Freedman is currently a Professor of Medicine and Director, Translational Research, at the University of Massachusetts Memorial Heart & Vascular Center and attends in the Division of Cardiology. She is also the Director of the High-Throughput Gene Expression and Biomarker Core Laboratory at UMass Medical School. Dr. Freedman graduated from Yale University, Tufts University School of Medicine, and completed residency and cardiology fellowship at the Massachusetts General Hospital and Brigham and Women?s Hospital, respectively. Dr. Freedman was elected to the A.S.C.I. and the Association of University Cardiologists. She is a Senior Editor for Circulation and on the editorial boards of ATVB and Circulation Research. She is currently the Chair of the National AHA Peer Review Sub-Committee.

Dr. Freedman is currently funded by the NIH through the NHLBI, NIAID and Common Fund. The major research initiatives in Dr. Freedman?s laboratory emphasize the regulation of immune and inflammatory pathways contributing to vascular disease. She runs two NIH funded laboratories; the first is a basic science laboratory that examines the role of immunity, infection, obesity, and inflammation on athero-thrombotic disease. The second is a translational laboratory that is currently collaborating with many basic and clinical groups using high-throughput and nano-chip and RNAseq technologies to study gene expression and provide translational data for a wide range of projects including the Framingham Heart Study, MESA and other observational cohorts and clinical trials. This laboratories expertise includes profiling of extracellular RNAs, miRNAs and low abundance gene expression studies for both large-scale clinical and basic studies.

Bruce Furie, MD

Photo coming soon Biography coming soon.

Zorina Galis, MD

Dr. Zorina Galis is an acknowledged pioneer of the current leading paradigm emphasizing the role of vascular remodeling in cardiovascular diseases, specifically as a basis for the atherosclerotic plaque vulnerability associated with acute coronary syndromes. Zorina is main author of numerous ?most read? and ?most cited? publications (Google Scholar profile, PubMed) and a popular science educator and speaker.

Zorina is currently the Chief of the NHLBI Vascular Biology and Hypertension Branch that provides leadership and support for basic, translational, and clinical extramural NIH research programs in basic vascular biology, and the etiology, pathogenesis, prevention, diagnosis, and treatment of vascular diseases and hypertension. Zorina also participates in organizing national and international scientific conferences and reviews funding applications for foreign government and non-government biomedical funding agencies.

Before joining the program staff in 2011, Zorina was an NHLBI grantee, expert reviewer and consultant. She rose through the academic ranks at Harvard Medical School, Boston, MA, Emory University, and Georgia Institute of Technology, Atlanta GA, up to a tenured position of Associated Professor of Medicine/Cardiology and of Biomedical Engineering. There, Zorina directed large, independently funded, interdisciplinary research teams and was essential in the initiation and funding of new cross-departmental and inter-university academic initiatives. Subsequently she held simultaneously the positions of Scientific Advisor, and then Chief Scientific Officer, Cardiovascular R&D at Eli Lilly and Co. and that of Professor of Vascular Surgery, at Indiana University, Indianapolis IN. Under her leadership, several new drug development projects were initiated and advanced to clinical development stage. She also championed and facilitated in-licensing and the formation of several major cross-functional science partnerships and business alliances, within pharma, and between academia and pharma.

Zorina was trained in physics, biophysics, cell biology, pathology, and vascular medicine at the University of Bucharest, Romania, McGill University School of Medicine, Montreal, Canada, and Harvard School of Medicine, Boston, USA.

Christopher K. Glass, MD, PhD, FAHA

Dr. Glass received M.D. and Ph.D. degrees from UC San Diego in 1984 and performed internship and residency training in Internal Medicine at Brigham and Women's Hospital. He returned to UC San Diego for fellowship training in Endocrinology and Metabolism and then joined the UC San Diego faculty. He is currently Professor of Medicine and Cellular and Molecular Medicine at UC San Diego and Adjunct Professor at the Salk Institute for Biological Sciences. Dr. Glass has had a long-standing interest in elucidating the molecular mechanisms by which sequence specific transcription factors, co-activators and co-repressors regulate the development and function of macrophages in the context of metabolic and neurodegenerative disease. His most recent studies have used a combination of genetics and genomics to define general molecular mechanisms underlying the selection and function of transcriptional regulatory elements that establish macrophage identity and cell-specific responses to diverse signaling inputs. Dr. Glass? laboratory is currently applying these approaches to understand pathological programs of gene expression that promote the development of atherosclerosis, diabetes and other chronic inflammatory diseases.

Jay Horton, MD

Dr. Jay D. Horton is a Professor of Internal Medicine and Molecular Genetics, Chief of the Division of Digestive and Liver Diseases, and holds the Robert C. and Veronica Atkins Chair in Obesity and Diabetes Research at UT Southwestern Medical Center. He obtained his B.S. and M.D. degrees from the University of Iowa and completed his internal medicine residency, gastroenterology fellowship, and Howard Hughes post-doctoral fellowship at UT Southwestern Medical Center. Dr. Horton is a former PEW scholar and member of the American Society for Clinical Investigation and Association of American Physicians. He serves as a consulting editor for Arteriosclerosis, Thrombosis, and Vascular Biology and as an associate editor of The Journal of Lipid Research.

In clinical digestive diseases, Dr. Horton has an interest in conditions that lead to fatty liver disease and obesity. Currently a major focus of the laboratory is to determine how transcriptional regulators of fat metabolism contribute to the development of fatty liver in various disease processes such as diabetes, obesity, and lipodystrophies.

In recent work, Dr. Horton has delineated the function of PCSK9, a protein secreted into the blood that determines plasma cholesterol levels through its action on LDL receptors in liver.

Paul Kubes, PhD

Photo coming soon Biography coming soon.

Jonathan R. Lindner, MD

Dr. Lindner is the M. Lowell Edwards Professor of Cardiology at the Knight Cardiovascular Institute at Oregon Health & Science University where he is the Director of Cardiovascular Imaging. He received his medical degree and residency training in internal medicine at the University of Texas Southwestern Medical School, and received his cardiovascular training at the University of Virginia. Dr. Lindner has expertise in the fields of cardiovascular imaging and microvascular physiology. His research laboratory has pioneered the use of contrast ultrasound for non-invasive molecular imaging of disease and the evaluation of microvascular dysfunction. Specific areas of research include: a) application of molecular imaging techniques for early detection of atherosclerosis and evaluation of new therapies for atherosclerosis; (b) molecular imaging of angiogenesis and stem cell therapy; (c) molecular imaging for early diagnosis of myocardial infarction; (d) microvascular dysfunction and endothelial abnormalities in sickle cell disease; (e) development of new methods for assessing peripheral arterial disease, and (f) novel methods for site-targeted gene and drug delivery with ultrasound. Dr. Lindner also serves as an Associate Editor for the Journal of the American Society of Echocardiography. He is on the Board of Directors and serves as the Vice-chair for the Exam Writing Committee for the National Board of Echocardiography.

Esther Lutgens, MD, PhD

Photo coming soon Biography coming soon.

Kathleen A. Martin, PhD

Dr. Kathleen Martin received her PhD degree from Case Western University and went on to postdoctoral training at Harvard Medical School in Cell Biology and signal transduction with Dr. John Blenis. In starting her lab at Dartmouth Medical School, she worked closely with academic surgeons in the Section of Vascular Surgery to apply her expertise in signaling and transcriptional control to vascular smooth muscle biology. This work provided new insights into the mechanisms of action of rapamycin, a potent drug-eluting stent agent. The finding that rapamycin, a known regulator of translation, was also a key regulator of smooth muscle-specific transcription has led to her current work on transcriptional and epigenetic control of smooth muscle phenotype. Her laboratory moved to the Yale School of Medicine Cardiovascular Research Center in 2009, where she is an Associate Professor of Medicine and Pharmacology. The Martin lab recently identified TET2 as a novel epigenetic regulator of smooth muscle plasticity and is currently employing in vitro and in vivo models to understand the coordinated actions of signaling pathways, kinases, transcription factors, and epigenetic modifiers in smooth muscle in pathologies including atherosclerosis, vascular injury response, and transplant vasculopathy. The lab also has interests in adipokine and prostacyclin signaling. She currently serves as a standing member of an NIH study section and as Vice Chair of the AHA Founders Affiliate Research Committee.

Alan Mast, MD, PhD

Alan Mast received a B.S, degree in biochemistry at the University of Illinois, graduating Summa Cum Laude. He enrolled in the Medical Scientist Training Program at Duke University where he obtained MD and PhD degrees and was elected into Alpha Omega Alpha. His doctoral research focused on the structure and function of the serpin superfamily of protease inhibitors. A key finding from this work was the description of the structural mechanism for the polymerization and inactivation of serpins that have now been associated with several diseases including ?1-antitrypsin deficiency. Dr. Mast performed residency training in Laboratory Medicine and post-doctoral research at Washington University in St. Louis where he began studies of Tissue Factor Pathway Inhibitor (TFPI). His graduate school and post-doctoral work led to receipt of the 1998 Presidential Early Career Award for Scientists and Engineers (PECASE) during the Clinton Administration. He served as Director of the Transfusion Medicine Service and Hematology and Coagulation Laboratories at the VA Medical Center in Memphis, TN and continued basic research studies of TFPI biology. He moved to Blood Center of Wisconsin in 2003 where he is currently a Senior Investigator at the Blood Research Institute. He is a recipient of an Established Investigator Award from the American Heart Association and maintains NIH-funded clinical and basic science research programs. His clinical research interests are in anemia and iron metabolism in blood donors. His basic research interests are in blood coagulation with a particular focus on TFPI.

Kiran Musunuru, MD, PhD, MPH

Photo coming soon Biography coming soon.

Christopher Overall, PhD

Dr. Overall is a Professor and Canada Research Chair in Protease Proteomics and Systems Biology, U.B.C. Vancouver. He completed his Ph.D. at the University of Toronto; and post-doctoral work with Dr. Michael Smith, Nobel Laureate. In 1997/1998 was a Visiting Senior Scientist at British Biotech, Oxford and in 2004/2008 a Visiting Senior Scientist at Novartis, Basel, and is now Honorary Professor, Albert-Ludwigs University Freiburg. Dr. Overall was 2002 CIHR Scientist of the Year, the UBC Killam Senior Researcher Award 2005, and the Chair of the 2003 Matrix Metalloproteinase and the 2010 Protease Gordon Research Conferences. With over 12,626 citations for his 210 papers and with an h factor of 62 and 22 Nature Review, Nature Journal, Cell Journal, Science and Science Signaling papers he is a leader in the field, which was recently recognized by the International Society of Proteolysis with the 2011 Lifetime Achievement Award; by the Matrix Biology Society of Australia and New Zealand with the 2012 Barry Preston Award; and in 2014 by the Tony Pawson Canadian National Proteomics Network Award for Outstanding Contribution and Leadership to the Canadian Proteomics Community. He is also an elected member of HUPO council, the Chromosome Centric Human Proteome Project (C-HPP) Executive Committee and is an Associate Editor of the Journal of Proteomics Research.

Len A. Pennacchio, PhD

Len Pennacchio is a Senior Staff Scientist in the Genomics Division at Lawrence Berkeley National Laboratory (LBNL) and Deputy Director of the DOE Joint Genome Institute. Dr. Pennacchio has an extensive background in mammalian genetics and genomics as well as with DNA sequencing technologies and their application to address outstanding issues in both the medical and energy sectors. He received his Ph.D. in 1998 from the Department of Genetics at Stanford University and performed his postdoctoral work as an Alexander Hollaender Distinguished Fellow at LBNL. He has authored over 125 peer-reviewed publications and in 2007 he received the Presidential Early Career Award for Scientists and Engineers (PECASE) from the White House for his in vivo studies on mammalian gene regulation.

Jorge Plutzky, MD

Photo coming soon Biography coming soon.

Katey Rayner, PhD

Katey Rayner is an Assistant Professor at the University of Ottawa Heart Institute in Ottawa, Canada where she directs the Cardiometabolic microRNA Laboratory. Dr. Rayner obtained her BSc from the University of Toronto, and her PhD from the University of Ottawa. Dr. Rayner?s doctoral work focused on the role of hormones, heat shock proteins and macrophage foam cells in the development of atherosclerosis. After her PhD, she pursued a postdoctoral fellowship first at Harvard Medical School/Massachusetts General Hospital then at New York University School of Medicine where Dr. Rayner helped to discover a role for microRNAs, specifically microRNA-33, in the regulation of HDL and its atheroprotective effects.

Since establishing her lab at the University of Ottawa, Dr. Rayner?s research program focuses on novel mechanisms that underlie the inflammatory processes of plaque progression and vulnerability, with a specific focus the intersection between macrophage inflammation and microRNAs as drivers of disease. Her group has uncovered a novel role for microRNA control of mitochondrial respiration in macrophage cholesterol efflux, which is aberrantly expressed in human atherosclerotic plaques. Dr. Rayner?s research also examines how extracellular microRNAs are mediating the progression of atherosclerosis in both human and animal models. She works closely with the UOHI Division of Interventional Cardiology and the Molecular Function and Imaging Group to develop novel therapeutics and diagnostics for clinical application in patients with unstable atherosclerotic disease.

Robert O. Ryan, PhD

Photo coming soon Biography coming soon.

Lakshmi Santhanam, PhD

Lakshmi Santhanam, PhD, is an Assistant Professor of Anesthesiology and Critical Care Medicine and Biomedical Engineering at Johns Hopkins University School of Medicine. Dr. Santhanam received her PhD in Chemical and Biological Engineering at Rensselaer Polytechnic Institute in the laboratory of Dr. Jonathan Dordick. Her postdoctoral training was in the area of vascular physiology at Johns Hopkins University SOM in the laboratory of Drs. Dan Berkowitz and Artin Shoukas. Her research is centered on the molecular mechanisms underlying vascular stiffening with particular emphasis on nitrosoredox signaling. Her interest in this area began when she was a postdoctoral fellow, when she demonstrated that arginase 1 S-nitrosylation contributes to its activation in the vasculature in the aging aorta. Since her recruitment to the faculty in 2008, she has demonstrated a role for the enzyme tissue transglutaminase (TG2) in vascular stiffness. In particular, she has shown that TG2 trafficking and activity are nitric oxide dependent in the aorta and that increased secretion and activity of TG2 contribute to the development of vascular stiffness in disease states. Ongoing efforts are directed at examining a potential non-catalytic function of TG2 in maintaining/dysregulating vascular function.

Ann Marie Schmidt, MD

Photo coming soon Biography coming soon.

Hiroaki Shimokawa, MD, PhD, FAHA

Dr. Shimokawa is Professor and the Chairman of the Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan. Dr. Shimokawa graduated from Kyushu University in 1979, obtained PhD degree in 1985, and has been appointed for the present position in 2005. His research projects include (1) molecular mechanisms of coronary artery spasm and atherosclerosis, (2) endothelial function, (3) development of innovative medical therapies, and (4) large clinical trials of heart failure and ischemic heart disease. He is well known for the development of animal models of coronary spasm and the identification of endothelium-derived hydrogen peroxide as an important endothelium-derived relaxing factor. He is also the pioneer for the development of extracorporeal cardiac shock wave therapy for the treatment of severe angina pectoris. He has published more than 450 peer-reviewed papers in the leading journals, such as Science, The Lancet, The Journal of Clinical Investigation, Circulation, The Journal of the American College of Cardiology, European Heart Journal, Circulation Research, and ATVB. He received the Satoh Award (the Society Award) of the Japanese Circulation Society (JCS) in 1999, the Jeffrey M. Hoeg Award of the American Heart Association (AHA) in 2006, the Japan Medical Association Award in 2012, and the William Harvey Lecture Award of the European Society of Cardiology (ESC) in 2014. He now serves as the Editor-in-Chief of Circulation Journal (JCS) as well as an Associate Editor of European Heart Journal (ESC) and ATVB (AHA) and a Senior Consulting Editor of Circulation Research (AHA), in addition to the editorial board members of many international journals, including Circulation and American Journal of Physiology.

Janet D. Sparks, PhD, FAHA

Photo coming soon Biography coming soon.

Ahmed Tawakol, MD

Dr. Tawakol is a cardiologist with a clinical and research focus in cardiovascular imaging. He graduated from Stanford Medical School and trained in Medicine, and Cardiology, at Brigham and Women?s Hospital then Nuclear Cardiology at Massachusetts General Hospital. He is Co-Director of the Cardiac MR PET CT Program and Director of Integrative Imaging trials Program at the Massachusetts General Hospital, Harvard Medical School.

Dr. Tawakol is a pioneer in the field of PET/CT and PET/MR imaging of atherosclerosis. A hypothesis that is central to his research is that assessment of atherosclerotic plaque biology provides an important supplement to classical structural information. Dr. Tawakol?s group provided the initial development and validation of molecular imaging as a tool to assess atherosclerotic plaque biology. Additionally, Dr. Tawakol played a key role in disseminating the approach and built an international network of collaborators to conduct multi-center trials. Within this paradigm, Dr. Tawakol has spearheaded several multi-center trials using advanced imaging to learn about disease mechanisms and to identify new treatments in humans.

Roger Y. Tsien, PhD

Roger Y. Tsien, born in 1952, received his A.B. in Chemistry and Physics from Harvard College in 1972. He received his Ph.D. in Physiology in 1977 from the University of Cambridge and remained as a Research Fellow until 1981. He then became an Assistant, Associate, then full Professor at the University of California, Berkeley. In 1989 he moved to the University of California, San Diego, where he is an Investigator of the Howard Hughes Medical Institute and Professor in the Depts. of Pharmacology and of Chemistry & Biochemistry. His honors include Artois-Baillet-Latour Health Prize (1995), Gairdner Foundation International Award (1995), Award for Creative Invention from the American Chemical Society (2002), Heineken Prize in Biochemistry and Biophysics (2002), Wolf Prize in Medicine (shared with Robert Weinberg, 2004), Rosenstiel Award (2006), E.B. Wilson Medal of the American Society for Cell Biology (shared with M. Chalfie, 2008), and Nobel Prize in Chemistry (shared with O. Shimomura and M. Chalfie, 2008). He is a member of the National Academy of Sciences and the Royal Society. Dr. Tsien is best known for designing and building molecules that either report or perturb signal transduction inside living cells. These molecules, created by organic synthesis or by engineering naturally fluorescent proteins, have enabled many new insights into signaling. He is now developing new ways to target contrast agents and therapeutic agents to tumors and sites of inflammation or thrombosis, based on their expression of extracellular proteases, and to highlight peripheral nerves to aid surgery.

Hannah Valantine, MD

Dr. Valantine is the NIH inaugural Chief Officer for Scientific Workforce Diversity, and a senior scientist in the intramural research program. She was recruited as a nationally recognized scientist to develop a comprehensive vision and strategies to diversify scientific applicant pools and pipelines, to expand recruitment methods and retention strategy, and to help promote inclusiveness and equity throughout the biomedical research community at large. Prior to starting this position in April 2014, Dr. Valantine was Professor of Cardiovascular Medicine and the Senior Associate Dean for Diversity and Leadership at Stanford School of Medicine, a leadership position she held since November 2004. She is nationally recognized for her transformative approaches to diversity, and is a recipient of the NIH Director?s Pathfinder Award for diversity in the scientific workforce. In this research effort she studied interventions for stereotype threat, which she proposed is an important factor that impedes the advancement of women in academic medicine. She has also pioneered new models to better align the academic work place with the needs of faculty in the 21st Century, for which Stanford gained national recognition as the recipient of the Alfred P. Sloan Award for faculty career flexibility. The model, Academic Biomedical Career Customization (ABCC), has received widespread attention with articles in Harvard Business review, New York Times, Nature, Chronicle of Higher Education and Academic Medicine.

Originally from The Gambia, West Africa, Dr. Valantine majored in biochemistry and studied medicine at St. George?s Hospital, London University. After completing internal medicine residency, she obtained her cardiology fellowship training at Royal Postgraduate Medical School, London. For her post-doctoral research fellowship training she moved to Stanford University, and undertook research focused on Echocardiography for the diagnosis of acute rejection. Dr. Valantine has maintained an active clinical research program that continues to yield high impact transformations in patient care. She was the Principle Investigator (PI) in a New England Journal of Medicine, (April 2010) article reporting a non-invasive approach for the diagnosis of acute heart transplant rejection, an innovation that represented a major paradigm shift in the way heart transplant patients are managed. She was the PI for an NIH-funded study in which she proposed (and confirmed) that the organ transplant is essentially a genome transplant, and that monitoring the level of donor DNA in the recipient?s blood as a marker of organ damage will detect early stages of rejection, published in Science Translational Medicine (June, 2014).

She has been the recipient of several research grants from the NIH and AHA, and has authored over 160 peer-reviewed publications in high impact journals including NEJM, PNAS, Cell, Science Translational Medicine, Circulation, Transplantation, Journal of Heart & Lung Transplant, 10 book chapters, and has been invited to be a presenter at over 100 lectures. She has served on many editorial boards including Journal of Heart & Lung Transplant, Transplantation and Circulation. She is a Past-President of the American Heart Association Western States Affiliate Board of Directors.

She is married to Denis von Kaeppler whose background is in Information Technology. They have two daughters. Aside from research and diversity, Dr. Valantine has a passion for travel, sailing, fine dining, visits to spas, and exercise.